(Reuters) — Top insulin maker Novo Nordisk (NYSE:NVO) slashed its long-term profit growth forecast today, signaling no let-up in its struggles to crack the U.S. market to which its chief executive said its commitment would not waver.
The Danish firm’s shares fell by as much as 19% to a 30-month low, wiping more than $15 billion off its market value after it halved the growth guidance to 5% from the 10% it predicted as recently as February.
Get the full story at our sister site, Drug Delivery Business News.
The post Novo Nordisk shares dive after long-term growth cut appeared first on MassDevice.
from MassDevice http://ift.tt/2feEVTn
Cap comentari:
Publica un comentari a l'entrada